Skip to content

Metastatic systemic therapy

TL;DR — Metastatic colorectal cancer treatment is a sequence, not a single regimen. The opening decision integrates resectability, symptoms, performance status, primary side and MMR/MSI, RAS, BRAF and HER2 biology (Biller 2021, PMID 33591350). Doublet fluoropyrimidine–oxaliplatin or –irinotecan plus a biologic is common; FOLFOXIRI–bevacizumab improves disease control in selected fit patients at greater toxicity (Cremolini 2020, PMID 32164906). Left-sided RAS/BRAF-wild-type tumors derive the clearest first-line benefit from anti-EGFR therapy, whereas bevacizumab is used across RAS groups (Rossini 2023, PMID 36913832). MSI-high/dMMR disease should receive checkpoint therapy, with nivolumab–ipilimumab now showing superior PFS to nivolumab alone as well as chemotherapy (André 2024, PMID 39602630; André 2025, PMID 39874977). Late-line trifluridine/tipiracil–bevacizumab and fruquintinib improve median survival by months rather than curing disease; toxicity, organ function and prior benefit should govern sequence (Prager 2023, PMID 37133585; Dasari 2023, PMID 37331369).

First decision: is metastatic disease potentially eradicable?

Before labeling disease palliative, a multidisciplinary team should assess liver, lung and peritoneal distribution, technical resectability, future liver remnant, extrahepatic disease and conversion potential.

Intent Definition Systemic goal
Upfront resectable All known disease can be cleared safely Perioperative risk reduction; avoid losing surgical window
Potentially convertible Response could create local-treatment option Maximize depth and probability of response
Unresectable disease control Local eradication not feasible Extend survival, control symptoms and preserve quality of life
Frail/symptom-directed Intensive therapy net harm likely Low-intensity control or supportive care

Technical resectability changes with expertise; tumor biology changes with time. Both should be revisited after response.

Baseline variables

Variable Treatment consequence
ECOG performance/frailty Doublet/triplet versus single agent/supportive care
Symptoms and tumor burden Need for rapid response
Liver/kidney function Drug selection and dose
Neuropathy Avoid/reduce oxaliplatin
Bowel obstruction/perforation risk Urgent local management; anti-VEGF caution
Primary in place Bleeding/obstruction risk
MMR/MSI Immunotherapy first line if dMMR/MSI-high
Extended RAS/BRAF Anti-EGFR eligibility and BRAF strategy
HER2/fusion/KRAS G12C Later targeted options
Primary side Anti-EGFR predictive context

Cytotoxic backbones

Regimen Components Main toxicities Common use
FOLFOX Infusional 5-FU/LV + oxaliplatin Neuropathy, cytopenia, mucositis First line; adjuvant-exposed sequence dependent
CAPOX Capecitabine + oxaliplatin Hand-foot, diarrhea, neuropathy Convenient doublet; renal function matters
FOLFIRI Infusional 5-FU/LV + irinotecan Diarrhea, neutropenia, alopecia First/second line
FOLFOXIRI 5-FU/LV + oxaliplatin + irinotecan More neutropenia, diarrhea, neuropathy Selected fit/high-burden or conversion aim
Fluoropyrimidine alone 5-FU/LV or capecitabine GI, marrow, cardiac, hand-foot Frail/lower-intensity treatment

Oxaliplatin and irinotecan sequences can yield similar overall exposure over the disease course; no backbone is intrinsically best without patient and tumor context.

Bevacizumab

Bevacizumab targets VEGF and can combine with fluoropyrimidine doublets or triplet. It does not require RAS wild type.

Toxicities include hypertension, proteinuria, bleeding, arterial/venous events, impaired wound healing and rare gastrointestinal perforation. Meta-analysis confirms increased hypertension and thromboembolism in colorectal regimens (Chitkara 2023, PMID 38069531).

Scheduling around surgery and untreated obstruction/perforation risk requires caution. An intact asymptomatic primary alone is not an automatic indication for resection.

Anti-EGFR antibodies

Cetuximab and panitumumab require extended RAS wild type. CALGB/SWOG 80405 found no significant overall-survival difference between cetuximab and bevacizumab with chemotherapy in KRAS-wild-type disease overall (median 30.0 versus 29.0 months) (Venook 2017, PMID 28632865).

Subsequent pooled analyses established primary side as a treatment-effect modifier: left-sided RAS/BRAF-wild-type cancers gain the clearest survival benefit from first-line anti-EGFR therapy; right-sided tumors generally do not (Rossini 2023, PMID 36913832).

Benefit feature Resistance feature
Left-sided primary Right-sided primary in first line
Extended RAS wild type KRAS/NRAS activating alteration
BRAF wild type BRAF V600E without matched BRAF strategy
HER2 nonamplified HER2 amplification
High response need Severe rash preference/quality burden

Toxicities include acneiform rash, paronychia, diarrhea, infusion reaction (cetuximab) and hypomagnesemia. Prophylactic skin care reduces burden.

Triplet induction

TRIBE2 compared FOLFOXIRI–bevacizumab with reintroduction after progression versus mFOLFOX6–bevacizumab followed by FOLFIRI–bevacizumab. Median PFS after two treatments was 19.2 versus 16.4 months (HR 0.74, 95% CI 0.63–0.88), with more grade 3–4 diarrhea and neutropenia during first line (Cremolini 2020, PMID 32164906).

STEAM and meta-analysis support higher response and disease control with triplet, but selected fit populations and added toxicity limit universal use (Hurwitz 2019, PMID 30552157; Shui 2018, PMID 30092572).

CAIRO5 specifically addressed initially unresectable liver-limited disease and showed that molecular profile and sidedness should determine the biologic paired with doublet/triplet conversion therapy (Bond 2023, PMID 37329889).

Maintenance and treatment breaks

Indefinite full-dose oxaliplatin produces cumulative neuropathy. Maintenance retains disease pressure with fewer drugs.

CAIRO3 randomized capecitabine–bevacizumab maintenance versus observation after CAPOX–bevacizumab induction. Maintenance improved the composite time to progression after reintroduction without worsening global quality of life, but overall-survival interpretation was influenced by subsequent therapy (Simkens 2015, PMID 25862517). Updated molecular analyses did not identify a simple subgroup that eliminates clinical judgment (Goey 2017, PMID 28911067).

Meta-analysis across bevacizumab-based maintenance trials confirms a progression-control effect but variable intensity and no equally large overall-survival signal, supporting individualization rather than mandatory continuous treatment (Stein 2016, PMID 26781523).

Strategy Advantage Cost
Fluoropyrimidine ± bevacizumab Delays progression, removes oxaliplatin Continued visits/toxicity
Treatment break Maximum recovery Earlier progression in some patients
Anti-EGFR maintenance Option after anti-EGFR induction Rash and resistance evolution
Reintroduction Reuses prior active drug after recovery Benefit depends on prior sensitivity

Second line

Second-line selection is driven by first-line exposure and resistance:

  • oxaliplatin first → irinotecan backbone;
  • irinotecan first → oxaliplatin backbone;
  • bevacizumab continuation or alternative antiangiogenic strategy may retain benefit;
  • anti-EGFR therapy for eligible patients not previously exposed;
  • biomarker-directed treatment when indicated.

Response, duration, residual toxicity and progression pattern matter more than line number alone.

Pooled TRIBE/TRIBE2 analysis shows that post-progression strategies after triplet induction remain heterogeneous and that reintroduction works best after prior sensitivity and adequate treatment-free interval (Rossini 2021, PMID 33024268).

MSI-high/dMMR disease

KEYNOTE-177 randomized first-line pembrolizumab versus chemotherapy. Median PFS was 16.5 versus 8.2 months (HR 0.60, 95% CI 0.45–0.80), with fewer grade ≥3 treatment-related adverse events, although early progression occurred in a subset (André 2020, PMID 33264544).

CheckMate 8HW compared nivolumab–ipilimumab with chemotherapy and demonstrated major PFS benefit in the first-line population (André 2024, PMID 39602630). A randomized comparison later showed nivolumab–ipilimumab superior to nivolumab monotherapy for PFS, with greater immune toxicity (André 2025, PMID 39874977).

Primary resistance still occurs. Confirming true dMMR/MSI-high status, steroid-free immune management and recognizing pseudoprogression versus progression are essential.

BRAF V600E disease

BRAF V600E defines an aggressive subgroup. After prior therapy, BEACON established encorafenib–cetuximab: updated median OS 9.3 versus 5.9 months for control (HR 0.61, 95% CI 0.48–0.77) (Tabernero 2021, PMID 33503393).

BREAKWATER moved encorafenib–cetuximab plus mFOLFOX6 into first line and improved response/PFS, changing the historical chemotherapy-first sequence (Kopetz 2025, PMID 39863775).

Later-line nonselective options

Regimen/trial Median OS result Major toxicity
TAS-102, RECOURSE 7.1 vs 5.3 months, HR 0.68 Neutropenia (Mayer 2015, PMID 25970050)
Regorafenib, CORRECT 6.4 vs 5.0 months, HR 0.77 Hand-foot, fatigue, hypertension, liver injury (Grothey 2013, PMID 23177514)
TAS-102 + bevacizumab, SUNLIGHT 10.8 vs 7.5 months, HR 0.61 Neutropenia, anemia, nausea (Prager 2023, PMID 37133585)
Fruquintinib, FRESCO-2 7.4 vs 4.8 months, HR 0.66 Hypertension, asthenia, hand-foot (Dasari 2023, PMID 37331369)

These median gains are meaningful at population level but heterogeneous. Patients with rapidly progressive poor-performance disease may not reproduce trial benefit.

Regorafenib dose escalation can improve tolerability compared with starting every patient at full dose; drug-specific reviews emphasize early liver, skin and blood-pressure monitoring (Carter 2014, PMID 24276917). Contemporary late-line algorithms increasingly place TAS-102–bevacizumab and fruquintinib ahead of older single-agent options while retaining performance status as the principal eligibility boundary (Ciracì 2025, PMID 39558030).

Rechallenge

Anti-EGFR-resistant RAS/EGFR-pathway clones decay after drug withdrawal, creating a biological basis for rechallenge (Parseghian 2019, PMID 30462160). Plasma ctDNA can exclude detectable resistance alterations before rechallenge; prospective studies show activity in molecularly selected patients, but optimal threshold and interval remain uncertain (Sunakawa 2020, PMID 35050760).

Oxaliplatin or irinotecan reintroduction is likewise reasonable after a meaningful prior response and recovery from limiting toxicity.

Response assessment

CT is the standard serial measure; CEA and ctDNA are complementary. Early radiographic progression should trigger confirmation of adherence, dosing and biology rather than automatic escalation in a clinically stable patient with ambiguous imaging.

For conversion intent, response should be reviewed by the surgeon/interventional team at predefined intervals; waiting for maximal response can allow liver injury or resistant progression.

Supportive care integrated with treatment

Symptom control, nutrition, pain, bowel function, venous-thromboembolism risk, psychosocial care and goals should be addressed from first line. Early palliative care is compatible with active anticancer treatment.

Dose reduction is not treatment failure. Relative dose intensity must be balanced against hospitalization, neuropathy, diarrhea and loss of function.

Open questions

  • Which patients need triplet induction rather than doublet plus biologic? (Cremolini 2020, PMID 32164906)
  • Should nivolumab–ipilimumab or single-agent PD-1 be preferred for low-volume dMMR disease given efficacy–toxicity tradeoffs? (André 2025, PMID 39874977)
  • What ctDNA threshold best selects anti-EGFR rechallenge? (Sunakawa 2020, PMID 35050760)
  • Can treatment breaks preserve quality of life without losing survival in molecularly defined subgroups? (Simkens 2015, PMID 25862517)
  • How should BREAKWATER-era BRAF sequencing integrate surgery for responding liver-limited disease? (Kopetz 2025, PMID 39863775)

References

  1. Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669-685. PMID 33591350
  2. Cremolini C, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(4):497-507. PMID 32164906
  3. Rossini D, et al. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. Eur J Cancer. 2023;184:106-116. PMID 36913832
  4. Andre T, et al. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024;391(21):2014-2026. PMID 39602630
  5. André T, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405(10476):383-395. PMID 39874977
  6. Prager GW, et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023;388(18):1657-1667. PMID 37133585
  7. Dasari A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41-53. PMID 37331369
  8. Chitkara A, et al. Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta-analysis. Cancer Med. 2023;12(24):21579-21591. PMID 38069531
  9. Venook AP, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017;317(23):2392-2401. PMID 28632865
  10. Hurwitz HI, et al. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist. 2019;24(7):921-932. PMID 30552157
  11. Shui L, et al. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis. Cell Physiol Biochem. 2018;48(5):1870-1881. PMID 30092572
  12. Bond MJG, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol. 2023;24(7):757-771. PMID 37329889
  13. Simkens LH, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385(9980):1843-52. PMID 25862517
  14. Goey KKH, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol. 2017;28(9):2128-2134. PMID 28911067
  15. Stein A, et al. Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis. Clin Colorectal Cancer. 2016;15(2):e29-39. PMID 26781523
  16. Rossini D, et al. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. Br J Cancer. 2021;124(1):183-190. PMID 33024268
  17. André T, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207-2218. PMID 33264544
  18. Tabernero J, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021;39(4):273-284. PMID 33503393
  19. Kopetz S, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med. 2025;31(3):901-908. PMID 39863775
  20. Mayer RJ, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909-19. PMID 25970050
  21. Grothey A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-12. PMID 23177514
  22. Carter NJ. Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer. Drugs Aging. 2014;31(1):67-78. PMID 24276917
  23. Ciracì P, et al. Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm. Nat Rev Clin Oncol. 2025;22(1):28-45. PMID 39558030
  24. Parseghian CM, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30(2):243-249. PMID 30462160
  25. Sunakawa Y, et al. RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer. JCO Precis Oncol. 2020;4:898-911. PMID 35050760